Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.
Express Scripts Holding Co. does not yet endorse the use of pharmacogenomic testing in areas where the value proposition is not clear, such as for the oncologic tamoxifen or the anti-clotting drugs warfarin or Bristol-Myers Squibb Co.’s Plavix (clopidogrel), according to the pharmacy benefit manager’s recently released 2011 Drug Trend Report.
“The evidence to support them is sparse (or even negative),” the PBM maintains. Express Scripts says it recommends its health...
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.
